Envarsus 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0030 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/01/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IA/0029/G 
This was an application for a group of variations. 
11/10/2022 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0028/G 
This was an application for a group of variations. 
25/07/2022 
SmPC, Annex 
C.I.3.a - To update sections 4.4 and 4.5 of the SmPC and 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
II, Labelling 
section 2 of the PL, to implement the signal 
and PL 
recommendation on drug interaction with cannabidiol 
leading to systemic calcineurin inhibitors and mTOR 
inhibitors serum levels increased and toxicity (EPITT 
19614). 
C.I.2.a - To update of sections 4.4, and 4.5 of the SmPC on 
the interaction with CYP3A4. Section 4.5 of the SmPC is 
also updated to include impact of direct acting antiviral 
therapy. In addition, to update section 4.8 of the SmPC to 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
add posterior reversible encephalopathy syndrome as an 
adverse reaction and update the SOC for febrile 
neutropenia from ‘General disorders and administration site 
conditions’ to ‘Blood and lymphatic system disorders’. 
PSUSA/2839/
Periodic Safety Update EU Single assessment - 
16/12/2021 
16/02/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202103 
tacrolimus (systemic formulations) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2839/202103. 
N/0027 
Minor change in labelling or package leaflet not 
09/12/2021 
16/02/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0024/G 
This was an application for a group of variations. 
04/06/2021 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0023/G 
This was an application for a group of variations. 
14/04/2021 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.7 - Administrative change - Deletion of 
manufacturing sites 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0022/G 
This was an application for a group of variations. 
15/01/2021 
n/a 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
N/0021 
Minor change in labelling or package leaflet not 
17/11/2020 
19/02/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0020 
A.5.b - Administrative change - Change in the name 
19/06/2020 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0019 
B.I.b.1.d - Change in the specification parameters 
25/05/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IA/0018/G 
This was an application for a group of variations. 
25/05/2020 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0016/G 
This was an application for a group of variations. 
26/02/2020 
19/02/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IA/0017/G 
This was an application for a group of variations. 
07/02/2020 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.b - Change in test procedure for the finished 
product - Deletion of a test procedure if an 
alternative method is already authorised 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0015 
B.III.1.a.1 - Submission of a new/updated or 
28/06/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
R/0014 
Renewal of the marketing authorisation. 
28/03/2019 
06/06/2019 
SmPC 
PSUSA/2839/
Periodic Safety Update EU Single assessment - 
13/12/2018 
12/02/2019 
Refer to Scientific conclusions and grounds recommending 
201803 
tacrolimus (systemic formulations) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2839/201803. 
IB/0013/G 
This was an application for a group of variations. 
10/10/2018 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
II/0008/G 
This was an application for a group of variations. 
14/12/2017 
n/a 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.i - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Where there is no 
monograph in the European/National Ph. for the AS, 
a change in specification from in-house to a non-
official/third country Ph. 
B.I.b.1.i - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Where there is no 
monograph in the European/National Ph. for the AS, 
a change in specification from in-house to a non-
official/third country Ph. 
B.I.b.1.i - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Where there is no 
monograph in the European/National Ph. for the AS, 
a change in specification from in-house to a non-
official/third country Ph. 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.II.a.1.a - Change or addition of imprints, bossing 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
Page 7/9 
 
 
 
 
 
imprints, bossing or other markings 
N/0011 
Minor change in labelling or package leaflet not 
05/05/2017 
12/02/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0010 
B.II.b.1.a - Replacement or addition of a 
24/04/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0009 
A.7 - Administrative change - Deletion of 
21/02/2017 
11/04/2017 
Annex II and 
manufacturing sites 
PL 
IB/0007 
C.I.z - Changes (Safety/Efficacy) of Human and 
11/04/2016 
11/04/2017 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IB/0006/G 
This was an application for a group of variations. 
21/12/2015 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tightening of in-process limits 
PSUSA/2839/
Periodic Safety Update EU Single assessment - 
03/12/2015 
n/a 
PRAC Recommendation - maintenance 
201503 
tacrolimus (systemic formulations) 
PSUSA/10337
Periodic Safety Update EU Single assessment - 
10/09/2015 
n/a 
PRAC Recommendation - maintenance 
/201501 
tacrolimus (systemic formulations) 
IAIN/0005 
B.II.b.2.c.1 - Change to importer, batch release 
20/08/2015 
14/12/2015 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0001/G 
This was an application for a group of variations. 
22/12/2014 
14/12/2015 
SmPC, Annex 
II and PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
C.I.12 - Inclusion or deletion of black symbol and 
explanatory statements for medicinal products in the 
list of medicinal products that are subject to 
additional monitoring 
Page 9/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
